Pasquale F. Innominato

机构：Betsi Cadwaladr University Health Board, Université Paris-Saclay, University of Warwick, Ysbyty Gwynedd Hospital NHS Trust · ORCID：0000-0002-0653-8261

发表论文 174 篇 · 总被引 5787 次 · h-index 43

代表论文

• Why does circadian timing of administration matter for immune checkpoint inhibitors’ efficacy? (2024 · British Journal of Cancer · 被引 98)
• Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis (2024 · ESMO Open · 被引 90)
• Circadian Regulation of Drug Responses: Toward Sex-Specific and Personalized Chronotherapy (2023 · The Annual Review of Pharmacology and Toxicology · 被引 88)
• Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial (2023 · The Lancet Oncology · 被引 84)
• Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis (2024 · Journal for ImmunoTherapy of Cancer · 被引 39)
• GATEKEEPER’s Strategy for the Multinational Large-Scale Piloting of an eHealth Platform: Tutorial on How to Identify Relevant Settings and Use Cases (2023 · Journal of Medical Internet Research · 被引 14)